SFM
PRLD icon

Sphera Funds Management’s Prelude Therapeutics PRLD Stock Holding History

Sphera Funds Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.44M Buy
1,019,832
+461,493
+83% +$2.01M 0.71% 46
2026
Q1 		$1.91M Buy
558,339
+435,587
+355% +$1.14M 0.3% 79
2025
Q4 		$356K Buy
+122,752
New +$207K 0.07% 94

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sphera Funds Management's PRLD Position: Q2 2026 in Review

Sphera Funds Management increased its Prelude Therapeutics (PRLD) stake by 83% in Q2 2026, buying an estimated $2.01M and bringing the position to 1,019,832 shares worth $5.44M. The position accounts for 0.71% of the portfolio, ranked #46.

Sphera Funds Management first reported a position in PRLD in Q4 2025 and has held it in 3 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Sphera Funds Management held 1,019,832 shares of Prelude Therapeutics worth $5.44M as of Q2 2026.
  • Sphera Funds Management bought 461,493 Prelude Therapeutics shares in Q2 2026, an estimated $2.01M.
  • Prelude Therapeutics made up 0.71% of Sphera Funds Management's portfolio in Q2 2026, its #46 holding.
  • Sphera Funds Management first reported a position in Prelude Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.